Skip to content

Clinical Evaluation of a Novel Incisional NPWT System

A Clinical Evaluation of a Novel, Single-Use, Negative Pressure Wound Therapy (NPWT) System for the Management of Closed Surgical Wounds

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04488666
Enrollment
23
Registered
2020-07-28
Start date
2021-01-26
Completion date
2025-06-16
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Wound

Keywords

incisional NPWT

Brief summary

A study of the first clinical use in humans of a novel NPWT system (npSIMS) to assess the suitability, safety and efficacy of the system for the management of closed surgical wounds

Detailed description

The purpose of this investigation is to test the functionality of a novel, non-electric NPWT device: npSIMS (negative pressure Surgical Incision Management System) from Aatru Medical LLC (Ohio, USA) which uses an exothermic chemical process to extract the oxygen from the air contained within the dressing (air contains 21% O2) and hence bring and maintain the system to between -160 and -80 mmHg below atmospheric pressure (760 mmHg). The dressing and the chemical reaction pump module can be manufactured for significantly less than the cost of electromechanical NPWT systems and can be profitably marketed at a discount to the cost of existing commercial devices. The Aatru Medical NPWT system could transform the economics and increase the availability of this therapy across the world.

Interventions

DEVICEnpSIMS

incisional NPWT

Sponsors

NAMSA
CollaboratorOTHER
Aatru Medical LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1\. Participant is male or female ≥ 18 years of age 2. Participant will undergo an elective sternotomy, thoracotomy, caesarean section (C-section) or skin surgery incision with closure by sutures or staples 3. Participant will undergo a surgical procedure resulting in a closed approximately linear incision between 5 cm and 13 cm in length inclusive so that the npSIMS dressing covers the wound with a minimum of 1 cm overlap at each end 4. Participant is willing and able to take part in the study and provide written informed consent. \-

Exclusion criteria

1. Participants will undergo post-surgical radiotherapy or chemotherapy 2. Participants who, in the opinion of the Investigator, have an existing health condition that would compromise their participation and follow-up in this study 3. Participant will undergo emergency surgery 4. Participant is sensitive to or known to have allergies to silicone/acrylic adhesives 5. Participant has malignancy in the wound bed or margins of the wound 6. Participant has wound with confirmed and untreated osteomyelitis 7. Participant has wound with non-enteric and unexplored fistulas 8. Participant has wound with necrotic tissue with eschar present 9. Participant has exposed arteries, veins, nerves or organs 10. Participant has exposed anastomotic sites

Design outcomes

Primary

MeasureTime frameDescription
Mean (median) number of days of negative pressure delivered to the incision up to day 77 daysTo assess the maintenance and reliability with which negative pressure is delivered for the 7-day NPWT period.

Secondary

MeasureTime frameDescription
Mean (median) clinician assessment of exudate management on 5-point Numerical Rating Score (NRS) at day 7 ±2 and at any npSIMS replacement.7 Days5 is excellent exudate management; 4 is good; 3 is adequate; 2 is poor; 1 is inadequate
Mean (median) days wear time of the adhesive dressing up to day 77 daysTo assess the wear time of the adhesive dressing
Mean (median) days longevity of the chemical vacuum source up to day 77 DaysTo assess the longevity of the chemical vacuum source
Mean (median) overall observer and participant scores in the POSAS - Patient Observer Scar Assessment Scale on day 14 ±2 clinic follow up.14 daysTo assess the appearance of the closed incision and scar. Each item of the POSAS is rated on a 10-point score. The lowest score is '1', which corresponds to the situation of normal skin (i.e. normal pigmentation, no itching). Score 10 equals the largest difference from normal skin (i.e. the worst imaginable scar or sensation)
Frequency of surgical wound complications according to the ASEPSIS wound score at day 14 ±2 clinic and day 30±2 remote follow up.30 DaysAssess the Frequency of Surgical site infections. A higher ASEPSIS score indicates impaired wound healing (a score of \>10 indicates an increasing probability and severity of infection)
Presence or absence of blisters on day 7 ±27 daysCondition of the peri wound skin
Frequency of adverse events (non-device related, and device related) up to day30 ±230 DaysTo assess the occurrence of adverse events
Mean (median) ease of use score from patients on 5-point NRS (numerical rating score) assessed at day 7 ±2. 5 is excellent ease of use; 4 is good; 3 is adequate; 2 is poor; 1 is inadequate7 days To assess the ease of use by patients assessmentsTo assess the ease of use by patients assessments
Mean (median) ease of use score from clinicians on 5-point NRS (numerical rating score) assessed at day 7 ±2. 5 is excellent ease of use; 4 is good; 3 is adequate; 2 is poor; 1 is inadequate7 daysTo assess the ease of use by clinicians assessments
Mean (median) score of overall clinician acceptability of the NPWT system (pump & dressing) on 5-point NRS assessed at day 14 ±2. 5 is Excellent incision management system; 4 is good; 3 is adequate; 2 is poor; 1 is inadequate14 daysTo assess overall clinician acceptability of the NPWT system
Mean (median) wound pain score using a 0 -10 NRS (numerical rating score) by the study participant each day up to day 7±2. 10 is worst imaginable pain; 0 is no pain.7 daysTo assess wound pain daily in the 7 day post-operative period

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026